Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vestibular system

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Vestibular system. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-005484-32 Sponsor Protocol Number: VN-FT-01 Start Date*: 2015-05-28
    Sponsor Name:Lund University
    Full Title: Double-blind, randomized placebo controlled study on the effect from cortisone treatment of vestibular neuritis - function, subjective well-being and stress
    Medical condition: Acute vestibular syndrome better known as Vestibular neuritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004863 10047392 Vestibular nerve damage LLT
    17.1 100000004854 10047388 Vestibular function disorder LLT
    17.1 100000004862 10051781 Vestibular paralysis LLT
    17.1 100000004854 10013285 Disorder vestibular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023099-13 Sponsor Protocol Number: V00251 ST 201 1A Start Date*: 2011-01-31
    Sponsor Name:PIERRE FABRE MEDICAMENT -IRPF- PIERRE FABRE INNOVATION
    Full Title: V0251 oral suspension efficacy and tolerance in vestibular neuritis. A randomised double-blind placebo controlled study
    Medical condition: The aim of this exploratory study is to assess the efficacy of the L-enantiomer V0251 oral form in the treatment of acute episodes of vertigo.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10047393 Vestibular neuronitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003927-45 Sponsor Protocol Number: SENS-111-201 Start Date*: 2017-05-04
    Sponsor Name:Sensorion SA
    Full Title: A multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patie...
    Medical condition: Acute Unilateral Vestibulopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047393 Vestibular neuronitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) ES (Prematurely Ended) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013702-14 Sponsor Protocol Number: BETNV009 Start Date*: 2010-08-13
    Sponsor Name:Hospital of the University of Munich
    Full Title: Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial
    Medical condition: vestibular failure (vestibular neuritis)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10013993 - Ear and labyrinth disorders 10047386 Vestibular disorder PT
    18.0 10029205 - Nervous system disorders 10029240 Neuritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002474-52 Sponsor Protocol Number: AM-125-CL-18-01 Start Date*: 2019-04-01
    Sponsor Name:Auris Medical AG
    Full Title: Multicenter randomized controlled phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following neurosurgery (TRAVERS)
    Medical condition: Treatment of acute peripheral vertigo
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10059614 Vestibular vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000388-15 Sponsor Protocol Number: VesPa Start Date*: 2016-08-31
    Sponsor Name:University of the University of Munich
    Full Title: Prophylactic treatment of vestibular paroxysmia with carbamazepine: a prospective, randomized, placebo-controlled, cross-over, multi-center trial
    Medical condition: The main symptoms of vestibular paroxysmia are brief attacks of rotatory or postural vertigo lasting seconds to a few minutes with or without ear symptoms (tinnitus and hypoacusis). As in trigemina...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005054-23 Sponsor Protocol Number: V00251 IV 201 Start Date*: 2007-12-07
    Sponsor Name:PIERRE FABRE MEDICAMENT - IRPF
    Full Title: A double-blind placebo controlled study of 1g, 2g and 4g V0251 efficacy and tolerance in vestibular neuritis.
    Medical condition: V0251 is a new investigational antivertiginous agent which is being developed for the treatment of symptomatic vertiginous crisis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047340 Vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) DE (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-013701-34 Sponsor Protocol Number: VMMET009 Start Date*: 2011-09-01
    Sponsor Name:Hospital of the University of Munich
    Full Title: Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo- controlled trial
    Medical condition: vestibular migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005215-46 Sponsor Protocol Number: VS_Nimodipine Start Date*: 2021-02-19
    Sponsor Name:Department of Neurosurgery, Medical University of Vienna
    Full Title: Intraoperative application of nimodipine to the facial and cochlear nerves during vestibular schwannoma resection to avoid spasm-related postoperative facial paralysis and deafness - a prospective ...
    Medical condition: Patients with vestibularis schwanomma undergoing microsurgical resection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001068-39 Sponsor Protocol Number: ECPAF11/16 Start Date*: 2018-07-24
    Sponsor Name:OMEQUI
    Full Title: Changes in the bone morphology of the post-extraction socket, preserved with platelet-rich fibrin and leukocytes (L-PRF) versus Conventional treatment
    Medical condition: Regenerative potential of L-PRF
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005770-26 Sponsor Protocol Number: KRONF2 Start Date*: 2023-10-20
    Sponsor Name:Medical University of Warsaw
    Full Title: Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe type 2 neurofibromatosis, in particular those excluded f...
    Medical condition: Neurofibromatosis type 2 is a genetically determined primary malignancy resulting from a mutation that disables the function of the cell division control gene and leads to neoplasia such as benign ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000523 Acoustic neuroma PT
    27.0 10010331 - Congenital, familial and genetic disorders 10029271 Neurofibromatosis, type 2 (acoustic neurofibromatosis) LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000156-35 Sponsor Protocol Number: NF2PET Start Date*: 2021-03-18
    Sponsor Name:Leiden University Medical Center
    Full Title: 89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.
    Medical condition: Neurofibromatosis type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001682-41 Sponsor Protocol Number: HLS03/2011 Start Date*: 2011-05-09
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Comparison of the efficacy and the safety of different schedules of administration of sub-lingual immunotherapy in patients with ragweed pollinosis: a phase III randomized and controlled clinical s...
    Medical condition: Subjects who are allergic to Ragweed.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003395-72 Sponsor Protocol Number: VitD@BPPV Start Date*: 2016-11-29
    Sponsor Name:Hospital of the University of Munich
    Full Title: Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind study (VitD@BPPV)
    Medical condition: The main symptoms of Benign Paroxysmal Positional Vertigo (BPPV) are brief, in part strong attacks of rotatory vertigo lasting seconds. These attacks can be provoked by reclination of the head or t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003412-23 Sponsor Protocol Number: V00251IV2024A Start Date*: 2012-01-25
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.
    Medical condition: V0251 is a new antivertiginous agent which is being developed for the treatment of symptomatic vertiginous crisis.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-000990-39 Sponsor Protocol Number: V00109 DI 301 Start Date*: 2008-05-22
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Reduction of the gingival inflammation by V0109 DI. Randomised, parallel groups, double blind study, V0109 DI versus placebo, in patients presenting gingivitis.
    Medical condition: Reduction of the gingival inflammation by V0109 DI.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012325 Dental and periodontal infections and inflammations HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-001545-25 Sponsor Protocol Number: CHDR1409 Start Date*: 2014-07-02
    Sponsor Name:Centre for Human Drug Research
    Full Title: Randomized, double-blind, placebo-controlled, three way crossover, double dummy, single centre study evaluating the effect of haloperidol 2 mg and lorazepam 1 mg on posturography and underlying sys...
    Medical condition: Healthy volunteers (balance disorders)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10049848 Balance disorder PT
    17.0 10029205 - Nervous system disorders 10004070 Balance difficulty LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004650-34 Sponsor Protocol Number: GR-2011-02348985 Start Date*: 2016-06-27
    Sponsor Name:IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO
    Full Title: Neuromodulation strategies to enhance the effects of gait rehabilitation in multiple sclerosis patients with cerebellar ataxia
    Medical condition: Multiple sclerosis with cerebellar ataxia
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003045-26 Sponsor Protocol Number: Pearl-PD Start Date*: 2015-10-23
    Sponsor Name:Umeå University Hospital
    Full Title: [18F] FE-PE2I PET/CT study of Dopamine Transporters in Early Parkinsonian disease.
    Medical condition: Patients with newly clinically diagnosed untreated idiopathic parkinsonism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001464-35 Sponsor Protocol Number: 104-201811 Start Date*: 2018-11-06
    Sponsor Name:Otonomy, Inc.
    Full Title: A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere’...
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 22:56:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA